




## STATE MEDICAID P&T COMMITTEE MEETING

Thursday, September 18, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 128



# MINUTES

### Committee Members Present:

Lisa Hunt, R.Ph.  
Kort Delost, R.Ph.  
Julia Ozbolt, M.D.

Jameson Rice, Pharm.D.  
Roger Martenau, M.D.  
Elizabeth Young, Pharm.D.

### Committee Members Excused:

Beth Johnson, R.Ph.

Ellie Brownstein, M.D.

### Dept. of Health/Div. of Health Care Financing Staff Present:

Richard Sorenson, RN  
Trevor Smith, CPhT

Tim Morley, R.Ph.  
Robyn Seely, Pharm.D.

### University of Utah Drug Information Center Staff Present:

Gary Oderda, RPh.

Bryan Larson, PharmD

### Other Individuals Present:

Cody Ball, Select Health  
Scott Larson, BMS

Marcus Shin, Forest Research  
Sean McCrun, Actavis

Meeting conducted by: Lisa Hunt

---

1. **Review and Approval of July Minutes:** Minutes for August were reviewed. Julia Ozbolt made a motion to approve the August minutes, Jameson Rice seconded the motion. All in favor.
2. **Housekeeping:** Lisa Hunt reminded people in attendance today to sign in. Lisa also reported that she is going to begin in looking at bids for supplemental rebates for 2015.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the DUR board finalized criteria for the PPI agents, new Synagis criteria, and topical immunomodulators in the last meeting. She said that for the next DUR meeting, the scheduled topics include a presentation by the OIG on controlled substances, and Rheumatoid Arthritis agents.
4. **Tetracycline agents:** Gary Oderda presented a review of the tetracycline drug class. He presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

## 5. Public Comment

- a. Marcus Shin (Actavis, Pylera) – He presented information about H. Pylori and the benefits of Pylera in treatment. In addition he presented other clinical information about the drug. He then offered to answer any questions from the committee.

## 6. Committee discussion (*Tetracycline agents*)

- a. Jameson Rice asked about the different salt formulations of doxycyclines and if they are both equally safe and effective. Gary Oderda said that they are the same if effectiveness and safety.
- b. Kort Delost said that there are lots of different products that are being reviewed, and they treat different things, even though they are in the same drug class. He also said that it will be important to keep products that have had a high utilization rate in the preferred category.
- c. Julia Ozbolt said that H. Pylori infections are very hard to treat, especially with the refugee population because of the 3 or 4 different ingredients that are needed to be taken concurrently. She said that the packs that have all ingredients together help these special populations.
- d. Lisa Hunt said that the drug class addition to the PDL that would only look at the individual ingredients and not the triple or quadruple therapy packs for H. Pylori and gastrointestinal problems. She said that this would review only the single ingredient products.
- e. Beth Young makes a motion to not include the triple or quadruple combination packs for treatment of H. Pylori or gastrointestinal diagnoses. These products will be included in a separate review. Julia Ozbolt seconds the motion. All in favor.
- f. Jameson Rice made a motion saying that the agents are equally safe and effective for inclusion on the PDL. Lisa Hunt seconds the motion. All in favor.

7. **Macrolide Antibiotic Agents:** Bryan Larson presented a review of the macrolide antibiotic drug class. He presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

## 8. Public Comment

- a. None

## 9. Committee discussion (*Macrolide Antibiotic Agents*)

- a. Lisa Hunt presented data from other states in how this class of drugs is coded in their respective PDLs.
- b. Kort Delost asked if ophthalmic agents were included in the review.
- c. Bryan Larson confirmed that the review was only on the oral agents.
- d. Discussion about some products including fidaxomicin and telithromycin and how they are not as safe as the other products, azithromycin, clarithromycin and erythromycin.

- e. Beth Young made a motion that the agents azithromycin, clarithromycin and erythromycin are equally safe and efficacious for their indicated uses for inclusion on the PDL. Julia Ozbolt seconded the motion. All in favor.
- f. Beth Young then said that the fidaxomycin should be considered in a different discussion.
- g. Beth Young then made a motion that both the fidaxomycin and telithromycin are not equally safe and effective, and should be considered to the DUR board for review for a possible clinical PA. Roger Martenau seconded the motion. All in favor.
- h. Jameson Rice asked if the committee should discuss the dosage formulations for the agents, and if there should be made a motion about including specific drug formulations
- i. Lisa Hunt said that a review will be done and if costs and utilization is similar, multiple formulations will be added to the PDL.
- j. Julia Ozbolt said the previous topic of tetracycline drug class should be discussed about the ease of dosing. The doxycycline is dosed twice a day whereas the tetracycline is dosed three times a day. She said that the twice a day dosing is a much better drug for patients being in compliance
- k. Lisa Hunt said that Utah Medicaid will look at cost of therapy per day when looking at the preferred status of specific drug classes.
- l. Julia Ozbolt made a motion to include doxycycline as a preferred agent based on utilization and ease of dosing and compliance in completing therapy. Jameson Rice seconded the motion. All in favor.

## **10. Meeting Adjourned**

- 11. Next meeting is scheduled for October 16, 2014. Aminoglycoside agents will be discussed.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)